Olympus said the FDA issued an import alert for some products made at three group facilities in Japan, restricting U.S. imports until further notice. It sees no additional impact on fiscal 2027 results and kept its forecast unchanged.
Key facts
The FDA action restricts imports into the United States of designated products made at the facilities.
The FDA announced the import alert on Oct. 19, 2026, U.S. time. The restriction will remain in place until further notice, putting the outlook for U.S. supplies of the affected products in focus. The facilities are in Hinode, Shirakawa and Aomori.
Olympus does not expect the measure to have an additional impact on consolidated results for the fiscal year ending March 2027 and will leave its previously announced forecast unchanged.
The company also said it does not anticipate a significant impact on customers. While it has maintained its forecast, it has not said when U.S. import restrictions might be lifted. Discussions with the FDA and any further notices will be closely watched.
Analyst take
Olympus sees no additional impact on consolidated results and says products already held by customers remain safe when used as directed, with no current effect on imports into other countries. But U.S. restrictions remain in place until further notice, making the affected supply scope and timing of any reversal important. The progress of Olympus' work with the FDA, as well as the near-term earnings impact, will be a key focus.
